Canaccord Genuity Cuts Price Target on Calamp Corp. (CAMP) to $23 Following 3Q Report
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pre-Open Stock Movers 12/22: (TKAI) (GSAT) (EYES) Higher; (OVAS) (RHT) (MLHR) Lower (more...)
December 22, 2016 9:25 AM ESTToday's Pre-Open Movers
Tokai Pharmaceuticals Inc. (NASDAQ: TKAI) 40.6% HIGHER; The company and Otic Pharma Ltd., a privately-held, clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT), today announced that the two companies, together with the shareholders of Otic... More
After-Hours Stock Movers 12/21: (XOMA) (MU) Higher; (OVAS) (RHT) (MLHR) Lower (more...)
December 21, 2016 5:45 PM ESTToday's After-Hours Movers
OvaScience (NASDAQ: OVAS) 32.7% LOWER; The Company will continue to make AUGMENTSM available to patients at partner clinics in Canada and Japan and maintain its current commercial footprint. However, the Company will slow its commercial expansion, reassess its ongoing and planned clinical studies of AUGMENT, and undertake a corporate restructuring. These changes will enable the Company to extend its cash position into the first quarter of 2019 and increase its focus on the development of OvaPrimeSM and OvaTureSM. In connection with this shift in strategy, President and... More
Calamp Corp. (CAMP) Misses Q3 EPS by 5c; Guides Q4 In-Line
December 21, 2016 4:07 PM ESTCalamp Corp. (NASDAQ: CAMP) reported Q3 EPS of $0.21, $0.05 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $83.4 million versus the consensus estimate of $83.93 million.
GUIDANCE:
Calamp Corp. sees Q4 2017 EPS of $0.25-$0.31, versus the consensus... More
Calamp Corp. (CAMP) CFO Rick Vitelle to Retire
December 21, 2016 4:04 PM ESTCalAmp (NASDAQ: CAMP) today announced that its Executive Vice President, Chief Financial Officer and Corporate Secretary, Rick Vitelle, plans to retire from the company after sixteen years of service. Mr. Vitelle will remain as CFO until his successor is found, to ensure an orderly and seamless transition. The company has initiated a comprehensive search... More
